INmune Bio Q2 2026 earnings: Tax rebate benefit narrows net loss

INmune Bio (NASDAQ: INMB) reported Q2 2026 revenue of $0, unchanged from a year earlier, and diluted EPS of -$0.05 compared with -$1.05 for the quarter ended June 30, 2026. Net loss narrowed to $1.3 million from $24.5 million, largely because R&D expense became a benefit and the prior-year period included a $16.5 million impairment. The company also advanced Ebstrocel toward regulatory filings and reported additional clinical and regulatory progress for XPro.

Core financial results

INmune Bio remained a pre-revenue biotechnology company during the quarter. The substantial year-over-year reduction in its loss primarily reflected the recognition of an additional Australian R&D tax rebate and the absence of the prior-year impairment, rather than revenue growth.

General and administrative expenses were nearly unchanged, indicating that the year-over-year improvement was concentrated in R&D accounting and the impairment comparison.

Pipeline and clinical progress

Ebstrocel moves closer to planned regulatory filings

INmune Bio received formal written alignment from the UK Medicines and Healthcare products Regulatory Agency across the manufacturing, non-clinical and clinical components of its planned Ebstrocel Marketing Authorization Application. The MHRA also approved the Pediatric Investigation Plan in less than three months, preserving the company’s planned 2026 UK filing timetable.

On the manufacturing side, the company processed its first commercial-ready umbilical cord tissues at the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in the UK. The transferred process is intended to support the planned confirmatory Phase 3 trial, regulatory submissions and potential future supply. Preparations for Phase 3 remain on track for the first patient treatment in Q4 2026.

INmune Bio also expanded its agreement with Anthony Nolan Cord Blood Bank to secure long-term access to umbilical cord tissue. This is relevant to the company’s ability to scale the CORDStrom platform, although Ebstrocel has not yet received regulatory approval.

XPro adds biomarker evidence and Fast Track status

In the Phase 2 MINDFuL trial, XPro produced a statistically significant treatment effect on a white-matter myelin MRI biomarker in the full modified intent-to-treat population, with a p-value of 0.0028, Cohen’s d of 0.46 and 200 participants. The effect was larger in the 100-patient biomarker-enriched population, where the p-value was 0.0098 and Cohen’s d was 0.59.

The published results also showed directionally consistent benefits across multiple endpoints in the protocol-defined Alzheimer’s disease with inflammation subgroup. No ARIA-E or ARIA-H events were observed. Separately, the FDA granted XPro Fast Track designation for early Alzheimer’s disease, allowing more frequent regulatory interactions as the company prepares a registrational Phase 2b/3 program.

Profitability, cash flow and balance sheet

Cash and cash equivalents were $18.4 million at June 30, 2026, down from $24.8 million at the end of 2025. The cash-flow statement covers the first six months of 2026 rather than Q2 alone: operating cash use was $6.6 million, compared with $14.2 million in the first half of 2025.

First-half investing cash use was $0.4 million, while financing activities provided $0.7 million. The company received an approximately $4.2 million Australian R&D tax rebate in July 2026, after the quarter ended, providing additional non-dilutive capital. The available data do not include a cash-runway estimate.

The loss narrowed for accounting reasons while revenue remained zero

The roughly $23.2 million year-over-year improvement in quarterly net loss is largely explained by two items. First, Q2 2025 included a $16.5 million impairment of acquired in-process R&D assets that did not recur. Second, the R&D line improved by approximately $6.6 million, moving from a $5.8 million expense to a $0.8 million benefit because of additional Australian tax rebate recognition.

Together, these items account for nearly all of the improvement, while general and administrative expense remained around $2.3 million. The lower loss therefore does not indicate that INmune Bio has begun generating commercial product revenue; the company’s financial position remains tied to development spending, regulatory execution and access to capital.

Upcoming regulatory and clinical milestones

The next scheduled milestones are concentrated in late 2026 and early 2027. These dates represent the company’s current plans and do not ensure filing acceptance or regulatory approval.

Recent insider transactions

The supplied insider data report no open-market purchases or sales during the past six months. They separately list three derivative-security exercises or conversions on July 2, 2026; these should not be classified as open-market purchases.

The transaction records alone do not establish insiders’ views about the company’s prospects.

Risks investors need to watch

• Regulatory execution: Ebstrocel and XPro have not been approved by the FDA, MHRA or another regulator. Planned filing dates could change, and submissions do not guarantee approval.
• Clinical uncertainty: XPro’s MRI biomarker findings support further development, but the registrational Phase 2b/3 program has not yet begun. Future trials must confirm safety and clinical benefit.
• Funding requirements: INmune Bio generated no quarterly revenue, used $6.6 million of operating cash in the first half and ended June with $18.4 million in cash. The company identifies access to substantial additional funding as a continuing risk.
• Manufacturing and supply: The commercial-ready tissue-processing milestone reduces part of the operational risk for Ebstrocel, but the company must still demonstrate consistent production for confirmatory development, regulatory review and any future commercialization.

Summary

INmune Bio’s Q2 2026 net loss narrowed sharply, but the change was driven by an R&D tax rebate benefit and the absence of a prior-year impairment rather than commercial revenue. Operationally, Ebstrocel made progress in UK regulatory alignment and manufacturing, while XPro added MRI biomarker evidence and FDA Fast Track designation. The main issues ahead are execution of the planned filings and trials, confirmation of clinical results, and funding the pipeline beyond the company’s current cash resources.